These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 21114196)

  • 1. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
    D'Amato G; Perticone M; Bucchioni E; Salzillo A; D'Amato M; Liccardi G
    Eur Ann Allergy Clin Immunol; 2010 Aug; 42(4):135-40. PubMed ID: 21114196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G; Renda T; Romeo P; Busceti MT; Maselli R
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of anti-IgE monoclonal antibody (omalizumab) in the treatment of bronchial asthma and allergic respiratory diseases.
    D'Amato G
    Eur J Pharmacol; 2006 Mar; 533(1-3):302-7. PubMed ID: 16464445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L; Sorkness CA
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review.
    D'Amato G; Stanziola A; Sanduzzi A; Liccardi G; Salzillo A; Vitale C; Molino A; Vatrella A; D'Amato M
    Multidiscip Respir Med; 2014; 9(1):23. PubMed ID: 24735949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW; Massanari M; Kianifard F; Geba GP
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
    D'Amato G; Bucchioni E; Oldani V; Canonica W
    Treat Respir Med; 2006; 5(6):393-8. PubMed ID: 17154668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
    Dewilde S; Turk F; Tambour M; Sandström T
    Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of allergic bronchial asthma with omalizumab - an anti-IgE monoclonal antibody.
    D'Amato G
    Expert Opin Biol Ther; 2003 Apr; 3(2):371-6. PubMed ID: 12662149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease.
    Berger WE
    Ann Allergy Asthma Immunol; 2002 Feb; 88(2):152-60; quiz 161-2, 208. PubMed ID: 11868919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
    D'Amato G; Salzillo A; Piccolo A; D'Amato M; Liccardi G
    Ther Clin Risk Manag; 2007 Aug; 3(4):613-9. PubMed ID: 18472983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-IgE in severe persistent allergic asthma.
    Fox H
    Respirology; 2007 Nov; 12 Suppl 3():S22-8; discussion S45-7. PubMed ID: 17956516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab: efficacy in allergic disease.
    Spector S
    Panminerva Med; 2004 Jun; 46(2):141-8. PubMed ID: 15507883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.
    Dodig S; Richter D; Cepelak I; Benko B
    Acta Pharm; 2005 Jun; 55(2):123-38. PubMed ID: 16179127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.